Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 송태진 | * |
dc.contributor.author | 박진 | * |
dc.contributor.author | 김지은 | * |
dc.date.accessioned | 2022-08-12T16:31:16Z | - |
dc.date.available | 2022-08-12T16:31:16Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 1085-9489 | * |
dc.identifier.other | OAK-32143 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/262380 | - |
dc.description.abstract | Vaccinations against the severe acute respiratory syndrome coronavirus 2 which causes COVID-19 have been administered worldwide. We aimed to investigate associations of COVID-19 vaccination with the occurrence of Guillain-Barré syndrome (GBS). We explored potential safety signals regarding the development of GBS using disproportionality analyses to compare COVID-19 vaccination with all adverse drug reaction (ADR) reports and influenza vaccines reported to VigiBase. As of October 15, 2021, a total of 2163 cases (0.13%) of GBS and its variants (including 46 cases of Miller-Fisher syndrome and 13 cases of Bickerstaff's encephalitis) were identified in entire ADR database after vaccination with the ChAdOx1 nCoV-19 (AstraZeneca, Cambridge, UK) or the two messenger RNA-based COVID-19 (BNT162b2; Pfizer and BioNTech) or mRNA-1273; Moderna) vaccines. The median time to onset of GBS after vaccination was around 2 weeks. The ChAdOx1 nCoV-19 and two messenger RNA-based COVID-19 vaccines demonstrated a higher risk for GBS against entire database (information component [IC]025 = 1.73 reporting odds ratio [ROR]025 = 3.51; IC025 = 1.07, ROR025 = 2.22, respectively). When compared with influenza vaccines, neither the ChAdOx1 nCoV-19 nor mRNA-based vaccines were found to be associated with greater risks of GBS (IC025 = −1.84, ROR025 = 0.11; IC025 = −1.86, ROR025 = 0.06, respectively). Although potential safety signals associated with GBS COVID-19 vaccines have been identified, the risk of GBS from COVID-19 vaccines were low and did not surpass those of influenza vaccines; however, because of the heterogeneity of the sources of information in the WHO pharmacovigilance database, further epidemiological studies are warranted to confirm these observations. © 2022 Peripheral Nerve Society. | * |
dc.language | English | * |
dc.publisher | John Wiley and Sons Inc | * |
dc.subject | COVID-19 | * |
dc.subject | Guillain-Barré syndrome | * |
dc.subject | Guillain-Barré syndrome variants | * |
dc.subject | SARS-CoV-2 | * |
dc.subject | vaccination | * |
dc.title | Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database | * |
dc.type | Article | * |
dc.relation.issue | 3 | * |
dc.relation.volume | 27 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 206 | * |
dc.relation.lastpage | 214 | * |
dc.relation.journaltitle | Journal of the Peripheral Nervous System | * |
dc.identifier.doi | 10.1111/jns.12507 | * |
dc.identifier.wosid | WOS:000823238900001 | * |
dc.identifier.scopusid | 2-s2.0-85133527310 | * |
dc.author.google | Kim J.-E. | * |
dc.author.google | Park J. | * |
dc.author.google | Min Y.G. | * |
dc.author.google | Hong Y.-H. | * |
dc.author.google | Song T.-J. | * |
dc.contributor.scopusid | 송태진(55507164200) | * |
dc.contributor.scopusid | 박진(57209628952) | * |
dc.contributor.scopusid | 김지은(36663634500) | * |
dc.date.modifydate | 20240318140943 | * |